Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Nabi (NABI) -- Ignore unavailable to you. Want to Upgrade?

To: Oak Tree who wrote (281)	9/20/2000 5:22:17 PM
From: Extra Pale	Read Replies (1) \| Respond to of 354

Replay of NABI conference call is available at 888.568.0907 Management is highly optimistic regarding StaphVax; and comment that perhaps selloff had something to do with over-reaction to press releases lacking in-depth analysis of trial results. Seems to me they may have a point; the pr stating that trial failed to meet "endpoint" sounded plenty of alarms with me. Mgmt explains that 12month endpoint is arbitrary, and that target market of surgery patients would not require long term immunization.